Assembly Biosciences, Inc. (ASMB)
| Market Cap | 435.78M +309.6% |
| Revenue (ttm) | 71.10M +121.1% |
| Net Income | -6.38M |
| EPS | -0.48 |
| Shares Out | 15.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 204,164 |
| Open | 28.88 |
| Previous Close | 28.65 |
| Day's Range | 26.42 - 28.89 |
| 52-Week Range | 13.13 - 39.71 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 48.75 (+77.79%) |
| Earnings Date | May 7, 2026 |
About ASMB
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next g... [Read more]
Financial Performance
In 2025, Assembly Biosciences's revenue was $72.30 million, an increase of 153.52% compared to the previous year's $28.52 million. Losses were -$6.12 million, -84.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price target is $48.75, which is an increase of 77.79% from the latest price.
News
Assembly Biosciences Transcript: Bank of America Global Healthcare Conference 2026
The discussion highlighted progress in advancing antiviral candidates for HSV and hepatitis D, with strong early clinical data and strategic partnerships driving pipeline momentum. Oral therapies aim to address unmet needs in efficacy, convenience, and transmission, with key data readouts expected by 2027.
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to...
Assembly Biosciences reports Q1 EPS (54c), consensus (64c)
Reports Q1 revenue $8.21M, consensus $6.95M. “The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs,” said Jason Okazaki, chi...
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inh...
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SO...
Assembly Biosciences price target raised to $43 from $39 at Guggenheim
Guggenheim raised the firm’s price target on Assembly Biosciences (ASMB) to $43 from $39 and keeps a Buy rating on the shares. The firm is updating its Assembly model to…
Assembly Biosciences files $400M mixed securities shelf
17:05 EDT Assembly Biosciences (ASMB) files $400M mixed securities shelf
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development pla...
Gilead opt-in ‘significantly de-risks’ Assembly pipeline, says H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on Assembly Biosciences (ASMB) with a $50 price target after the company announced that Gilead (GILD) exercised its option to license…
Gilead exercises option to license Assembly helicase-primase inhibitor programs
Gilead (GILD) and Assembly Biosciences (ASMB), announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus helicase-primase inhibitor programs, includ...
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combine...
Assembly Biosciences Transcript: Study Result
Phase I-B studies of ABI-1179 and ABI-5366 in recurrent genital herpes showed impressive efficacy, with weekly dosing regimens achieving up to 98% reduction in HSV-2 shedding and strong safety profiles. Both candidates are advancing toward phase II, with further optimization and regulatory discussions planned.
Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials
Assembly Biosciences (ASMB) announced interim results from two Phase 1b studies of its investigational long-acting herpes simplex virus helicase-primase inhibitors in participants seropositive for HSV...
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179,...
Assembly Biosciences price target raised to $40 from $29 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $40 from $29 and keeps an Outperform rating on the shares. The firm updated the company’s…
Assembly Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The conference highlighted strong interim results for two potent, long-acting herpes virus therapies, with over 90% reduction in viral shedding and lesions, and detailed plans for upcoming data releases and phase 2 trials. The company is also advancing oral hepatitis delta and HBV programs, supported by a robust financial position and partnership with Gilead.
Assembly Biosciences reports Q3 EPS (72c), consensus (65c)
Reports Q3 revenue $10.79M, consensus $9.32M. “Our third quarter was marked by significant progress across our pipeline and important data releases, particularly the impressive interim antiviral activ...
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent ge...
Assembly Biosciences announces Phase 1b data for ABI-4334
Assembly Biosciences (ASMB) announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator, CAM, ABI-4334 featured in a late-breaking poster presentation at the Ame...
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov...
Assembly Biosciences files to sell 6.98M shares of commons stock for holders
16:22 EDT Assembly Biosciences (ASMB) files to sell 6.98M shares of commons stock for holders
Assembly Biosciences Announces Upcoming Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, t...
Assembly Biosciences presents interim Phase 1b data for ABI-5366
Assembly Biosciences (ASMB) announced that interim Phase 1b clinical data for its long-acting herpes simplex virus helicase-primase inhibitor candidate ABI-5366 are featured in a late-breaking oral pr...
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in...